Article
Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial.
Cancer research - 15 Dec 2020
Wong Connie C, Baum Jason, Silvestro Angela, Beste Michael T, Bharani-Dharan Bharani, Xu Siyan, Wang Ying A, Wang Xiaoshan, Prescott Margaret F, Krajkovich Lynne, Dugan Margaret, Ridker Paul M, Martin Anne-Marie, Svensson Eric C
Abstract excerpt
In the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), inhibition of the IL1β inflammatory pathway by canakinumab has been shown to significantly reduce lung cancer incidence and mortality. Here we performed molecular characterization of CANTOS patients who developed lung cancer during the study, including circulating tumor DNA (ctDNA) and soluble inflammatory biomarker analysis. Catalogue of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.